The anticancer effects of HDAC inhibitors require the immune system

Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFN...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology Vol. 3; no. 1; p. e27414
Main Authors: West, Alison C, Smyth, Mark J, Johnstone, Ricky W
Format: Journal Article
Language:English
Published: United States Taylor & Francis 01.01.2014
Landes Bioscience
Subjects:
anticancer immunity
anticancer therapy
Author's View
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
anticancer immunity
anticancer therapy
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
ISSN:2162-402X, 2162-4011, 2162-402X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.4161/onci.27414